|
|
Article: CSL Biotherapies Contracts with U.S. Department of Health and Human Services (HHS) to Provide Novel A (H1N1) Influenza Vaccine Antigen.
- Article from:
- Business Wire
- Article date:
- May 29, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Initial Delivery Anticipated to Begin in September, Pending Regulatory Approval
KING OF PRUSSIA, Pa. -- CSL Biotherapies, Inc. announced today that it has signed a contract with the U.S. Department of Health and Human Services (HHS) to provide Novel A (H1N1) influenza vaccine antigen in bulk form to support HHS' pandemic influenza preparedness efforts. The initial order under contract will be for an amount of at least $180 million. CSL Biotherapies anticipates initial delivery of the antigen by September, subject to regulatory approval. The new vaccine antigen will be tested in clinical trials funded by HHS.
CSL Biotherapies has also negotiated an option ...